Search research articles
Contact Us
Filters
Showing results (31-40 of 80) with videos related to
Page
of 8
Sort By:
Current Alzheimer Research
|
June 25, 2005
Validation of the neuroinflammation cycle as a drug discovery target using integrative chemical biology and lead compound development with an Alzheimer's disease-related mouse model
Wenhui Hu, Hantamalala Ralay Ranaivo, Jeffrey M Craft, et al.
International Review of Neurobiology
|
August 7, 2007
Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function-based and target-based discovery approaches
Linda J Van Eldik, Wendy L Thompson, Hantamalala Ralay Ranaivo, et al.
Current Alzheimer Research
|
July 18, 2006
De novo and molecular target-independent discovery of orally bioavailable lead compounds for neurological disorders
Laura K Wing, Heather A Behanna, Linda J Van Eldik, et al.
Brain Research
|
June 9, 2009
Enhanced microglial activation and proinflammatory cytokine upregulation are linked to increased susceptibility to seizures and neurologic injury in a 'two-hit' seizure model
Kathleen C Somera-Molina, Sangeetha Nair, Linda J Van Eldik, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
August 8, 2009
Molecular properties and CYP2D6 substrates: central nervous system therapeutics case study and pattern analysis of a substrate database
Laura K Chico, Heather A Behanna, Wenhui Hu, et al.
Journal of Molecular Neuroscience : MN
|
September 23, 2003
Discovery of a new class of synthetic protein kinase inhibitors that suppress selective aspects of glial activation and protect against beta-amyloid induced injury: a foundation for future medicinal chemistry efforts focused on targeting Alzheimer's disease progression
D Martin Watterson, Anastasia V Velentza, Magdalena Zasadzki, et al.
Bioorganic & Medicinal Chemistry
|
October 3, 2009
Effect of potential amine prodrugs of selective neuronal nitric oxide synthase inhibitors on blood-brain barrier penetration
Richard B Silverman, Graham R Lawton, Hantamalala Ralay Ranaivo, et al.
Journal of Neuroinflammation
|
April 7, 2017
Retention of normal glia function by an isoform-selective protein kinase inhibitor drug candidate that modulates cytokine production and cognitive outcomes
Zhengqiu Zhou, Adam D Bachstetter, Claudia B Späni, et al.
Journal of Neuroinflammation
|
July 8, 2011
Microglial p38α MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Aβ)
Adam D Bachstetter, Bin Xing, Lucia de Almeida, et al.
Neuroscience Research
|
October 9, 2007
Inhibition of glial cell activation ameliorates the severity of experimental autoimmune encephalomyelitis
Xiaoli Guo, Kazuaki Nakamura, Kuniko Kohyama, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 80) with videos related to
Sort By:
Page
of 8
Current Alzheimer Research
|
June 25, 2005
Validation of the neuroinflammation cycle as a drug discovery target using integrative chemical biology and lead compound development with an Alzheimer's disease-related mouse model
Wenhui Hu, Hantamalala Ralay Ranaivo, Jeffrey M Craft, et al.
International Review of Neurobiology
|
August 7, 2007
Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function-based and target-based discovery approaches
Linda J Van Eldik, Wendy L Thompson, Hantamalala Ralay Ranaivo, et al.
Current Alzheimer Research
|
July 18, 2006
De novo and molecular target-independent discovery of orally bioavailable lead compounds for neurological disorders
Laura K Wing, Heather A Behanna, Linda J Van Eldik, et al.
Brain Research
|
June 9, 2009
Enhanced microglial activation and proinflammatory cytokine upregulation are linked to increased susceptibility to seizures and neurologic injury in a 'two-hit' seizure model
Kathleen C Somera-Molina, Sangeetha Nair, Linda J Van Eldik, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
August 8, 2009
Molecular properties and CYP2D6 substrates: central nervous system therapeutics case study and pattern analysis of a substrate database
Laura K Chico, Heather A Behanna, Wenhui Hu, et al.
Journal of Molecular Neuroscience : MN
|
September 23, 2003
Discovery of a new class of synthetic protein kinase inhibitors that suppress selective aspects of glial activation and protect against beta-amyloid induced injury: a foundation for future medicinal chemistry efforts focused on targeting Alzheimer's disease progression
D Martin Watterson, Anastasia V Velentza, Magdalena Zasadzki, et al.
Bioorganic & Medicinal Chemistry
|
October 3, 2009
Effect of potential amine prodrugs of selective neuronal nitric oxide synthase inhibitors on blood-brain barrier penetration
Richard B Silverman, Graham R Lawton, Hantamalala Ralay Ranaivo, et al.
Journal of Neuroinflammation
|
April 7, 2017
Retention of normal glia function by an isoform-selective protein kinase inhibitor drug candidate that modulates cytokine production and cognitive outcomes
Zhengqiu Zhou, Adam D Bachstetter, Claudia B Späni, et al.
Journal of Neuroinflammation
|
July 8, 2011
Microglial p38α MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Aβ)
Adam D Bachstetter, Bin Xing, Lucia de Almeida, et al.
Neuroscience Research
|
October 9, 2007
Inhibition of glial cell activation ameliorates the severity of experimental autoimmune encephalomyelitis
Xiaoli Guo, Kazuaki Nakamura, Kuniko Kohyama, et al.
Page
of 8